Important Information
SINGULAIR is indicated for prophylaxis and chronic treatment of asthma in patients aged 12 months and older.
SINGULAIR should not be used as rescue medication to treat acute asthma episodes. Patients should be advised to have appropriate rescue medication available.
Although the dose of inhaled corticosteroid may be reduced gradually under medical supervision, SINGULAIR would not be abruptly substituted for inhaled or oral corticosteroids.
Use of SINGULAIR may not eliminate the need for inhaled or systemic corticosteroids. Patients should not decrease the dose or stop taking any other anti-asthma medications unless instructed by a physician.
Safety and effectiveness of SINGULAIR in patients younger than 12 months have not been established.
Patients should be advised to take SINGULAIR daily as prescribed, even when they are asymptomatic, as well as during periods of worsening asthma, and to contact their physician if their asthma is not well controlled.
This site is intended only for healthcare professionals of the United States, its territories, and Puerto Rico. SINGULAIR is a registered trademark of Merck & Co., Inc.
For general information and other services for physicians
MerckProductServices is a trademark of Merck & Co., Inc.
Merck OnCall® is a registered trademark of Merck & Co., Inc.
MerckServices is a trademark of Merck & Co., Inc.